K. Kast, K. Rhiem, B. Wappenschmidt, E. Hahnen, J. Hauke et al., Prevalence of BRCA1/2 germline mutations in 21 401 families with breast and ovarian cancer, Journal of Medical Genetics, vol.53, issue.7, pp.465-71, 2016.

R. Chiorean, C. Braicu, and I. Berindan-neagoe, Another review on triple negative breast cancer. Are we on the right way towards the exit from the labyrinth? Breast, vol.22, pp.1026-1059, 2013.

P. Kumar and R. Aggarwal, An overview of triple-negative breast cancer, Arch Gynecol Obstet, vol.293, issue.2, pp.247-69, 2016.

W. D. Foulkes, I. E. Smith, and J. S. Reis-filho, Triple-negative breast cancer, N Engl J Med, vol.363, issue.20, pp.1938-1986, 2010.

M. Kasum, L. Beketid-ore?kovid, P. F. Peddi, S. Ore?kovid, and R. H. Johnson, Fertility after breast cancer treatment, Eur J Obstet Gynecol Reprod Biol, vol.173, pp.13-21, 2014.

R. Ronn and H. Holzer, Breast cancer and fertility: an update, Curr Opin Support Palliat Care, vol.9, issue.3, pp.285-93, 2015.

C. Dabrosin, An overview of pregnancy and fertility issues in breast cancer patients, Ann Med, vol.47, issue.8, pp.673-681, 2015.

S. Shiovitz and L. A. Korde, Genetics of breast cancer: a topic in evolution, Ann Oncol, vol.26, issue.7, pp.1291-1300, 2015.

A. Cinkaya, M. Akin, and A. Sengul, Evaluation of treatment outcomes of triple-negative breast cancer, J Cancer Res Ther, vol.12, issue.1, pp.150-154, 2016.

T. Byrski, T. Huzarski, and R. Dent, Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients, Breast Cancer Res Treat, vol.115, pp.359-63, 2009.

D. P. Silver, A. L. Richardson, and A. C. Eklund, Efficacy of neoadjuvant cisplatin in triplenegative breast cancer, J Clin Oncol, vol.28, pp.1145-53, 2010.

S. M. Rodríguez-pinilla, D. Sarrió, and E. Honrado, Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas, Clin Cancer Res, vol.12, pp.1533-1542, 2006.

K. D. Voduc, M. C. Cheang, S. Tyldesley, K. Gelmon, T. O. Nielsen et al., Breast cancer subtypes and the risk of local and regional relapse, J Clin Oncol, vol.28, pp.1684-91, 2010.

L. A. Carey, C. M. Perou, and C. A. Livasy, breast cancer subtypes, and survival in the Carolina breast cancer study, JAMA, vol.295, pp.2492-2502, 2006.

R. Dent, M. Trudeau, and K. I. Pritchard, Triple-negative breast cancer: clinical features and patterns of recurrence, Clin Cancer Res, vol.13, pp.4429-4434, 2007.

M. Ono, H. Tsuda, and C. Shimizu, Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer, Breast Cancer Res Treat, vol.132, pp.793-805, 2012.

L. A. Carey, E. C. Dees, and L. Sawyer, The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes, Clin Cancer Res, vol.13, pp.2329-2334, 2007.

R. Rouzier, C. M. Perou, and W. F. Symmans, Breast cancer molecular subtypes respond differently to preoperative chemotherapy, Clin Cancer Res, vol.11, pp.5678-5685, 2005.

F. Kassam, K. Enright, and R. Dent, Survival outcomes for patients with metastatic triplenegative breast cancer: implications for clinical practice and trial design Clin Breast Cancer, vol.9, pp.29-33, 2009.

G. M. Freedman, P. R. Anderson, and T. Li, Locoregional recurrence of triple-negative breast cancer after breast-conserving surgery and radiation Cancer, vol.115, pp.946-951, 2009.

C. Liedtke, C. Mazouni, K. R. Hess, F. André, A. Tordai et al., Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer, J Clin Oncol, vol.26, issue.8, pp.1275-81, 2008.
DOI : 10.1200/jco.2007.14.4147

T. Byrski, J. Gronwald, and T. Huzarski, Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy, J Clin Oncol, vol.28, pp.375-379, 2010.
DOI : 10.1200/jco.2008.20.7019

D. Mauri, N. Pavlidis, and J. P. Ioannidis, Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis, J Natl Cancer Inst, vol.97, issue.3, pp.188-94, 2005.

L. Mauriac, G. Macgrogan, and A. A. , Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up, Ann Oncol, vol.10, issue.1, pp.47-52, 1999.
DOI : 10.1023/a:1008337009350

URL : https://academic.oup.com/annonc/article-pdf/10/1/47/19477127/10-1-47.pdf

S. M. Scholl, B. Asselain, and T. Palangie, Neoadjuvant chemotherapy in operable breast cancer, Eur J Cancer, vol.27, issue.12, pp.1668-71, 1991.
DOI : 10.1016/0277-5379(91)90442-g

B. Fisher, A. Brown, and E. Mamounas, Effect of preoperative chemotherapy on localregional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18, J Clin Oncol, vol.15, issue.7, pp.2483-93, 1997.

N. Wolmark, J. Wang, E. Mamounas, J. Bryant, and B. Fisher, Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18, J Natl Cancer Inst Monogr, issue.30, pp.96-102, 2001.
DOI : 10.1093/oxfordjournals.jncimonographs.a003469

P. Rastogi, S. J. Anderson, and H. D. Bear, Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27, J Clin Oncol, vol.26, issue.5, pp.778-85, 2008.
DOI : 10.1200/jco.2007.15.0235

J. A. Van-der-hage, C. J. Van-de-velde, J. P. Julien, M. Tubiana-hulin, C. Vandervelden et al., Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902, J Clin Oncol, vol.19, issue.22, pp.4224-4261, 2001.

L. Gianni, J. Baselga, and W. Eiermann, Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer, J Clin Oncol, vol.27, issue.15, pp.2474-81, 2009.

V. Minckwitz, G. Kümmel, S. Vogel, and P. , Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study, J Natl Cancer Inst, vol.100, issue.8, pp.552-62, 2008.

V. Minckwitz, G. Rezai, M. Loibl, and S. , Capecitabine in addition to anthracycline-and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study, J Clin Oncol, vol.28, issue.12, pp.2015-2038, 2010.

V. Minckwitz, G. Untch, M. Nüesch, and E. , Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neoadjuvant chemotherapy trials, Breast Cancer Res Treat, vol.125, issue.1, pp.145-56, 2011.
URL : https://hal.archives-ouvertes.fr/hal-00589967

L. Gianni, W. Eiermann, and V. Semiglazov, Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomized controlled superiority trial with a parallel HER-2 negative cohort, Lancet, vol.375, issue.9712, pp.377-84, 2010.

V. Minckwitz, G. Eidtmann, H. Loibl, and S. , Integrating bevacizumab, everolimus, and lapatinib into current neoadjuvant chemotherapy regimen for primary breast cancer. Safety results of the GeparQuinto trial, Ann Oncol, vol.22, issue.2, pp.301-307, 2011.

L. Gianni, T. Pienkowski, and Y. H. Im, Neoadjuvant pertuzumab (P) and trastuzumab (H): antitumor and safety analysis of a randomized phase II study
DOI : 10.1158/0008-5472.sabcs10-s3-2

J. H. Goldie and A. J. Coldman, A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate, Cancer Treat Rep, vol.63, pp.1727-1760, 1979.

E. P. Mamounas, NSABP Protocol B-27. Preoperative doxorubicin plus cyclophosphamide followed by preoperative or postoperative docetaxel, Oncology (Huntingt), issue.6, pp.37-40, 1997.

E. P. Mamounas, Overview of National Surgical Adjuvant Breast Project neoadjuvant chemotherapy studies, Semin Oncol, vol.25, issue.2, pp.31-36, 1998.

T. J. Powles, T. F. Hickish, A. Makris, S. E. Ashley, M. E. O'brien et al., Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer, J Clin Oncol, vol.13, pp.547-52, 1995.

A. Makris, T. J. Powles, S. E. Ashley, J. Chang, T. Hickish et al., A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer, Ann Oncol, vol.9, pp.1179-84, 1998.

J. S. Mieog, J. A. Van-der-hage, and C. J. Van-de-velde, Preoperative chemotherapy for women with operable breast cancer, Cochrane Database Syst Rev, vol.2, p.5002, 2007.

M. Untch, V. Möbus, and W. Kuhn, Intensive dose-dense compared with conventionally scheduled preoperative chemotherapy for high-risk primary breast cancer, J Clin Oncol, vol.27, pp.2938-2983, 2009.

H. Bonnefoi, M. Piccart, and J. Bogaerts, on behalf of the EORTC 10994/BIG 1-00 Study Investigators. TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial, Lancet Oncol, vol.12, pp.527-566, 2011.

M. Untch, M. Rezai, and S. Loibl, Neoadjuvant treatment with trastuzumab in HER2positive breast cancer: results from the GeparQuattro study, J Clin Oncol, vol.28, pp.2024-2055, 2010.

M. Untch, G. Von-minckwitz, and G. E. Konecny, and the Arbeitsgemeinschaft Gynäkologische Onkologie PREPARE investigators. PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensifi ed chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin-cyclophosphamide followed by paclitaxel with or without darbepoetin alfa in primary breast canceroutcome on prognosis, Ann Oncol, vol.22, pp.1999-2006, 2011.

M. Untch, P. A. Fasching, and G. E. Konecny, Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups, J Clin Oncol, vol.29, pp.3351-57, 2011.

L. D. Feldman, G. N. Hortobagyi, A. U. Buzdar, F. C. Ames, and G. R. Blumenschein, Pathological assessment of response to induction chemotherapy in breast cancer, Cancer Res, vol.46, pp.2578-81, 1986.